A Chinese male presenting with decreased sensation, muscle weakness, and myotonia — the inability to relax his muscles — was…
Yedida Y Bogachkov PhD
Yedida Y. Bogachkov is a science writer for BioNews. She holds a PhD in cellular and molecular pharmacology from the University of Illinois at Chicago. Prior to joining BioNews, she was conducting scientific research analyzing cancer genomics. She’s a Chicago native and hasn’t moved out of her hometown. Yes, she actually likes snow and enjoys having all four seasons. Yedida likes being out in nature, and in her free time, she can be found outside enjoying the fresh air or baking (inside). She is, unsuccessfully, trying to persuade the rest of her family to enjoy hiking. Yedida is excited to bring her passion for science and her desire to help people to BioNews.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Yedida Y Bogachkov PhD
Two newly reported mutations in the MPZ gene resulted in Charcot-Marie-Tooth (CMT) disease type 1B in Chinese patients, according…
A Japanese man was found to have a new mutation in the PRPS1 gene, which caused Charcot-Marie-Tooth disease type…
Two research projects focused on developing gene-editing therapies for Charcot-Marie-Tooth disease type 2 (CMT2) — both launched with seed…
Nerve damage caused by mutations in the HINT1 gene are as common among Greek patients with Charcot-Marie-Tooth disease (CMT) or…
Children with Charcot-Marie-Tooth (CMT) disease are more likely to be on either extreme of the body mass index, either…
A researcher from Belgium who is developing a new cell-based model for Charcot-Marie-Tooth (CMT) disease has been awarded nearly…
A retrospective study by the National Institutes of Health (NIH) suggests that healthcare costs for those with rare diseases have…
PXT3003, a potential treatment for Charcot–Marie–Tooth type 1A (CMT1A) being developed by Pharnext, showed “promising” results and…